Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Rarity Bioscience AB
AB
Active
Org 5593199960
Dag Hammarskjölds Väg 56 E, 752 37
Uppsala
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2021 · 5 years old
20-49 employees
Overvåg
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Rarity Bioscience AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
2M
4M
6M
8M
0M
2021
0M
2022
2M
2023
1M
2024
7M
2025
EBITDA
SEK millions
0M
-8M
-15M
-23M
-30M
-2M
2021
-10M
-400%
2022
-14M
-40%
2023
-20M
-43%
2024
-24M
-20%
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
28
115
2 016
1 352
7 404
Staff expenses
—
−5 692
−10 171
−13 654
−19 436
EBITDA
−2 488
−9 691
−14 264
−20 008
−24 485
Depreciation & amort.
−11
−41
−41
−205
−222
EBIT
−2 499
−9 733
−14 305
−20 214
−24 707
Net financials
12
55
714
802
842
Profit before tax
−2 488
−9 677
−13 591
−19 412
−23 865
Tax
−0
—
—
—
−0
Net profit
−2 488
−9 677
−13 591
−19 412
−23 865
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
13 381
30 693
23 294
70 580
48 193
Equity
12 537
27 859
19 668
67 285
43 516
Long-term debt
0
—
—
—
18
Short-term debt
844
2 834
3 626
3 295
4 658
Total debt
844
2 834
3 626
3 295
4 676
Financial ratios
5-year trend
EBITDA-margin
-330.7%
This company
15.8%
Market median
-2193% vs market
2021
2025
Soliditetsgrad
90.3%
This company
38.2%
Market median
+136% vs market
2021
2025
Egenkapitalforrentning
-54.8%
This company
18.4%
Market median
-398% vs market
2021
2025
Nettoresultatgrad
-322.3%
This company
8.1%
Market median
-4079% vs market
2021
2025
Aktivomsætning
0.15×
This company
1.12×
Market median
-87% vs market
2021
2025
Gæld/egenkapital
0.11×
This company
0.62×
Market median
+82% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-06-01 – 2021-12-31
View
PDF
More on Rarity Bioscience AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
